Study of tepotinib and ivonescimab for non-small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, tepotinib and ivonescimab, for people with a certain type of advanced non-small cell lung cancer that has a change called MET exon 14 skipping. The treatment aims to shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-small cell lung cancer (stage IIIB/C or IV) that has a specific genetic change called MET exon 14 skipping.
- You must have at least one tumor that can be measured on scans.
- You must not have other known cancer-driving genetic changes (for example, in EGFR, ALK, ROS1, RET, NTRK, HER2, KRAS, or BRAF).
- You must not have had prior treatment with drugs like bevacizumab or ramucirumab (angiogenesis inhibitors).
- You must be 18 or older and able to perform daily activities with minimal assistance (ECOG 0-2).
- You must not have certain serious health conditions like interstitial lung disease, bleeding problems, or poorly controlled high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (ivonescimab with either dato-DXd or osimertinib) for people with advanced lung cancer that has a specific EGFR gene mutation and has already been treated with other therapies. The goal is to see if this combination can help control the cancer better than current options.
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
This trial tests a combination of two drugs (chidamide and ivonescimab) for people with advanced non-small cell lung cancer that stopped responding to initial immunotherapy and has a specific protein marker (YAP) at high levels. It aims to see if this new combination can help when standard immunotherapy no longer works.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.